RE: Accustem fopar20 Aug 2021 00:08
That’s not how it works. Some of the TILS shares are held by the bank in the US that issued ADRs in respect of them for trading on Nasdaq. One Accustem share was issued for each Tiziana share held by investors including those held in the US on account of the ADRs (TLSA). Whilst it was possible to pick up extra Accustem shares by selling Tils after the record date and buying TLSA, it does not change the total number of Accustem shares that were issued - it was one per share.
Any company can create extra shares to sell to new investors, which is why there are now further Accustem shares. The company can sell these further shares for cash which can be used, hopefully, to generate further growth and shareholder value. Whether this dilutes the value of the original shares or increased the value of them will depend on how much cash is raised per share and whether it adds to the value of the company. Seems to me Accustem needs to raise cash to develop Stemprinter/Spare to maximise the value. This will take time so patience is needed but I think we will get an update soon.
Also, if you are genuinely interested in Accustem demerger or frustrated, or just want to vent the best place is the Accustem Telegram group rather than this board.
Would add that Accustem were never ‘free shares’ and it is unsurprising to me that TILS headed back to pre Accustem levels after the demerger; what surprised me a bit was that it took as long as it did but maybe that’s to do with the number of private investors who got involved on the back of COVID. Maybe also because for several months Accustem value was still in the TLSA - there really should have been a transatlantic price differential.
Can’t see Tils dropping much further from here but who knows. All the above IMVHO. GLA,
Mike